Neutrophil-to-lymphocyte ratio predicts PSA response and prognosis in prostate cancer: A systematic review and meta-analysis

PLoS ONE

Volumn 11, Issue 7, 2016, Pages

  Cao, Jian ^a,b   Zhu, Xuan ^a   Zhao, Xiaokun ^a   Li, Xue Feng ^b   Xu, Ran ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; CABAZITAXEL; DOCETAXEL; KETOCONAZOLE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BIOCHEMICAL RECURRENCE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; HUMAN; LOCALIZED PROSTATE CANCER; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PREDICTION OF PROSTATE SPECIFIC ANTIGEN RESPONSE; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE FREE SURVIVAL; SYSTEMATIC REVIEW; CELL COUNT; CYTOLOGY; IMMUNOLOGY; LYMPHOCYTE; MALE; META ANALYSIS; METABOLISM; NEUTROPHIL; PROGNOSIS; PROSTATIC NEOPLASMS;

CELL COUNT; HUMANS; LYMPHOCYTES; MALE; NEUTROPHILS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84978224309     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0158770     Document Type: Article

References (59)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-tieulent J, Jemal A. Global Cancer Statistics, 2012. CA a cancer J Clin. 2015; 65: 87-108. doi: 10.3322/caac.21262
2. Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D, et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol. 2008; 9: 445-452. doi: 10.1016/S1470-2045(08)70104-9 PMID: 18424233
3. Ferlay J, Soerjomataram II, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136: E359-86. doi: 10.1002/ijc.29210 PMID: 25220842
4. Potosky AL, Kessler L, Gridley G, Brown CC, Horm JW. Rise in prostatic cancer incidence associated with increased use of transurethral resection. JNatlCancer Inst. 1990; 82: 1624-1628.
5. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995; 273: 548-552. doi: 10.1001/jama.273.7.548 PMID: 7530782
6. Li J, Djenaba JA, Soman A, Rim SH, Master VA. Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007. Prostate Cancer. 2012; 2012: 691380. doi: 10.1155/2012/691380 PMID: 23251806
7. Heidenreich A, Bolla M, Joniau S, Mason MD, Matveev V, Mottet N, et al. Guidelines on Prostate Cancer. Update. 2011; 53: 31-45. doi: 10.1016/j.eururo.2007.09.002
8. Pezaro C, Woo HH, Davis ID. Prostate cancer: Measuring PSA. Intern Med J. 2014; 44: 433-440. doi: 10.1111/imj.12407 PMID: 24816306
9. Grivennikov SI, Greten FR, Karin M. Immunity, Inflammation, and Cancer. Cell. Elsevier Inc.; 2010; 140: 883-899. doi: 10.1016/j.cell.2010.01.025 PMID: 20303878
10. Yin X, Xiao Y, Li F, Qi S, Yin Z, Gao J. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer. Medicine (Baltimore). 2016; 95: e2544. doi: 10.1097/MD.0000000000002544
11. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of Observational Studies. 2008; 283.
12. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8: 16. doi: 10.1186/1745-6215-8-16 PMID: 17555582
13. Sutton AJ, Abrams KR, Jones DR, Sheldon T a, Song F. Methods for Meta-analysis in Medical Research. 2000; 309.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-188. 0197-2456(86)90046-2 [pii] PMID: 3802833
15. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56: 455-463. doi: 10.1111/j.0006-341x.2000.00455.x PMID: 10877304
16. Lorente D, Mateo J, Templeton AJ, Zafeiriou Z, Bianchini D, Ferraldeschi R, et al. Baseline neutrophillymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 2015; 26: 750-755. doi: 10.1093/annonc/mdu587 PMID: 25538172
17. Kwon YS, Han CS, Yu JW, Kim S, Modi P, Davis R, et al. Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer. Clin Genitourin Cancer. Elsevier Inc.; 2015; 1-8. doi: 10.1016/j.clgc.2015.07.018
18. Chung CH. Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy. Oncologist. 2008; 13: 725-732. doi: 10.1634/theoncologist.2008-0012 PMID: 18586928
19. Zhanhg J, Wang HT, Yang Q, Du J, Jia WY. castration-resistant prostate cancer treated with docetaxelbased chemotherapy. TUMOUR. 2015; 35: 333-339. doi: 10.3781/j.issn.1000-7431.2015.33.707
20. Nuhn P, Vaghasia AM, Goyal J, Zhou XC, Carducci MA, Eisenberger MA, et al. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel. BJU Int. 2014; 114: E11-E17. doi: 10.1111/bju.12531 PMID: 24529213
21. Zhang G-M, Zhu Y, Ma X-C, Qin X-J, Wan F-N, Dai B, et al. Pretreatment Neutrophil-to-Lymphocyte Ratio. Medicine (Baltimore). 2015; 94: e1473. doi: 10.1097/MD.0000000000001473
22. Yao A, Sejima T, Iwamoto H, Masago T, Morizane S, Honda M, et al. High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy. Int J Urol. 2015; 22: 827-833. doi: 10.1111/iju.12839 PMID: 26087772
23. Sümbül AT, Sezer A, Abali H, Köse F, Gültepe I, Mertsoylu H, et al. Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel. Int Urol Nephrol. 2014; 1-5. doi: 10.1007/s11255-014-0664-7
24. van Soest RJ, Templeton AJ, Vera-Badillo FE, Mercier F, Sonpavde G, Amir E, et al. Neutrophil to lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann Oncol. 2014; 2014: 743-749. doi: 10.1093/annonc/mdu569
25. Shafique K, Proctor MJ, McMillan DC, Qureshi K, Leung H, Morrison DS. Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study. Prostate Cancer Prostatic Dis. Nature Publishing Group; 2012; 15: 195-201. doi: 10.1038/pcan.2011. 60 PMID: 22343838
26. Poyet C, Adank J-P, Keller E, Mortezavi A, Rabgang T, Pfister B, et al. Mp66-05 Pretreatment Systemic Inflamatory Response Parameters Do Not Predict the Outcome in Men With Prostate Cancer Undergoing Radical Prostatectomy. J Urol. 2015; 193: e817. doi: 10.1016/j.juro.2015.02.2358
27. Leibowitz-Amit R, Templeton AJ, Omlin A, Pezaro C, Atenafu EG, Keizman D, et al. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2014; 25: 657-62. doi: 10.1093/annonc/mdt581 PMID: 24458472
28. Sonpavde G, Pond GR, Armstrong AJ, Clarke SJ, Vardy JL, Templeton AJ, et al. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. Elsevier Inc; 2014; 12: 317-324. doi: 10.1016/j.clgc.2014.03.005 PMID: 24806399
29. Sharma V, Cockerill PA, Viers BR, Rangel LJ, Carlson RE, Karnes RJ, et al. Mp6-05 the Association of Preoperative Neutrophil To Lymphocyte Ratio With Oncologic Outcomes Following Radical Prostatectomy for Prostate Cancer. J Urol. Elsevier Ltd; 2015; 193: e55-e56. doi: 10.1016/j.juro.2015.02.252
30. McDonald AC, Vira MA, Vidal AC, Gan W, Freedland SJ, Taioli E. Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease-the 2001-2008 National Health and Nutrition Examination Survey. Prostate. 2014; 74: 561-7. doi: 10.1002/pros.22782 PMID: 24435840
31. Linton A, Pond G, Clarke S, Vardy J, Galsky M, Sonpavde G. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Clin Genitourin Cancer. Elsevier Inc; 2013; 11: 423-430. doi: 10.1016/j.clgc.2013.04.020 PMID: 23816526
32. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'reilly DSJ, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer. Elsevier Ltd; 2011; 47: 2633-2641. doi: 10.1016/j.ejca.2011.03.028 PMID: 21724383
33. Lee H, Jeong SJ, Hong SK, Byun S-S, Lee SE, Oh JJ. High preoperative neutrophil-lymphocyte ratio predicts biochemical recurrence in patients with localized prostate cancer after radical prostatectomy. World J Urol. 2015; doi: 10.1007/s00345-015-1701-6
34. Templeton AJ, Pezaro C, Omlin A, McNamara MG, Leibowitz-Amit R, Vera-Badillo FE, et al. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-tolymphocyte ratio. Cancer. 2014; 120: 3346-3352. doi: 10.1002/cncr.28890 PMID: 24995769
35. Minardi D, Scartozzi M, Montesi L, Santoni M, Burattini L, Bianconi M, et al. Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer. Springerplus. Springer International Publishing; 2015; 4: 255. doi: 10.1186/s40064-015-1036-1 PMID: 26085975
36. McLachlan JM, Chan DL, Crumbaker MA, Marx GM. Neutrophil-lymphocyte ratio prior to steroids as a prognostic marker in men with metastatic castration-resistant prostate cancer. Cancer Treat Commun. Elsevier; 2015; 4: 81-85. doi: 10.1016/j.ctrc.2015.06.001
37. Bahig H, Taussky D, Delouya G, Nadiri A, Gagnon-Jacques A, Bodson-Clermont P, et al. Neutrophil count is associated with survival in localized prostate cancer. BMC Cancer. BMC Cancer; 2015; 15: 594. doi: 10.1186/s12885-015-1599-9 PMID: 26292807
38. Wei Y, Jiang YZ, Qian WH. Prognostic role of NLR in urinary cancers: A meta-analysis. PLoS One. 2014; 9. doi: 10.1371/journal.pone.0092079
39. Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis. Journal of the National Cancer Institute. 2014. doi: 10.1093/jnci/dju124
40. Li M-X, Liu X-M, Zhang X-F, Zhang J-F, Wang W-L, Zhu Y, et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer. 2014; 134: 2403-13. doi: 10.1002/ijc.28536 PMID: 24122750
41. Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau C-S, et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015; 522: 345-8. doi: 10.1038/nature14282 PMID: 25822788
42. Piccard H, Muschel RJ, Opdenakker G, Tazzyman S, Niaz H, Murdoch C, et al. Neutrophil-mediated tumour angiogenesis: Subversion of immune responses to promote tumour growth. Semin Cancer Biol. 2013; 23: 149-158. doi: 10.1016/j.critrevonc.2011.06.004 PMID: 23410638
43. Li XF, Chen DP, Ouyang FZ, Chen MM, Wu Y, Kuang DM, et al. Increased autophagy sustains the survival and pro-tumourigenic effects of neutrophils in human hepatocellular carcinoma. J Hepatol. 2015; 62: 131-139. doi: 10.1016/j.jhep.2014.08.023 PMID: 25152203
44. Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S. Tumor associated macrophages and neutrophils in cancer. Immunobiology. Elsevier GmbH.; 2013; 218: 1402-1410. doi: 10.1016/j.imbio.2013.06.003 PMID: 23891329
45. Ramanathan S, Gagnon J, Ilangumaran S. Antigen-nonspecific activation of CD8+ T lymphocytes by cytokines: relevance to immunity, autoimmunity, and cancer. Arch Immunol Ther Exp (Warsz). 2008; 56: 311-23. doi: 10.1007/s00005-008-0033-2
46. Muranski P, Restifo NP. Adoptive immunotherapy of cancer using CD4+ T cells. Curr Opin Immunol. 2009; 21: 200-208. doi: 10.1016/j.coi.2009.02.004 PMID: 19285848
47. Zhang Y, Eliav Y, Shin SU, Schreiber TH, Podack ER, Tadmor T, et al. B lymphocyte inhibition of antitumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion. Cancer Immunol Immunother. 2013; 62: 87-99. doi: 10.1007/s00262-012-1313-6 PMID: 22772949
48. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009; 9: 162-74. doi: 10.1038/nri2506 PMID: 19197294
49. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009; 58: 49-59. doi: 10.1007/s00262-008-0523-4 PMID: 18446337
50. Xu J, Escamilla J, Mok S, David J, Priceman S, West B, et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 2013; 73: 1-13. doi: 10.1158/0008-5472.CAN-12-3981
51. Wu C Te, Hsieh CC, Lin CC, Chen WC, Hong JH, Chen MF. Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells. J Mol Med. 2012; 90: 1343-1355. doi: 10.1007/s00109-012-0916-x PMID: 22660275
52. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009; 182: 4499-4506. doi: 10.4049/jimmunol.0802740 PMID: 19342621
53. Kim J, Bae J, Tam M. Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment. 2016; 2016. doi: 10.1155/2016/6058147 PMID: 26966341
54. Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson A-M, Saad F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods. Elsevier B.V.; 2009; 348: 9-17. doi: 10.1016/j.jim.2009.06.004 PMID: 19552894
55. Flammiger A, Bayer F, Cirugeda-Kühnert A, Huland H, Tennstedt P, Simon R, et al. Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. APMIS. 2012; 120: 901-8. doi: 10.1111/j.1600-0463.2012.02924.x PMID: 23009114
56. Ness N, Andersen S, Valkov A, Nordby Y, Donnem T, Al-Saad S, et al. Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer. Prostate. 2014; 74: 1452-1461. doi: 10.1002/pros.22862 PMID: 25111810
57. Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM, et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res. 2007; 13: 6947-6958. doi: 10.1158/1078-0432.CCR-07-0842 PMID: 18056169
58. Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I, et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med. 2005; 201: 1257-1268. doi: 10.1084/jem. 20042028 PMID: 15824085
59. Kawahara T, Yokomizo Y, Ito Y, Ito H, Ishiguro H, Teranishi J, et al. Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer. BMC Cancer. BMC Cancer; 2016; 16: 111. doi: 10.1186/s12885-016-2134-3 PMID: 26883640